EUVIMEDEUVIMED entdecken
Crossref

The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center

Jennifer A Afranie-Sakyi iD, Eldrida Randall, Ross Fasano iD, Morgan L McLemore iD, Fuad El Rassi iD

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Jennifer A Afranie-Sakyi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Morehouse School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sickle cell disease (SCD) is the most common hemoglobinopathy in North America. The life expectancy of SCD has extended into adulthood with screenings, preventative care, and hydroxyurea. However, comorbidities arise as adults with SCD age, leading to early mortality.

Methods

We conducted a retrospective chart review of the Georgia Comprehensive Sickle Cell Center at Grady Health System, analyzing records of deceased SCD patients from 2013 to 2020.

Results

Amongst the 72 patients analysed, majority had severe complications from SCD and at least 1 cardiovascular comorbidity. The median age of death was 44 (STD = 15.5) for all genotypes with the median age of death at 39 (STD = 14.26) for SS and Sβ0 genotypes ( n = 51). There was no difference in the median age of death for patients who maintained regular clinic visits (a visit in the last 6 months prior to death) compared to those who did not. Despite hydroxyurea's known benefits in reducing SCD morbidity and mortality, less than 50% of patients had a prescription.

Conclusion

As new therapies are approved, their impact on SCD‐related morbidity and mortality must be evaluated. Improving access to, and education about, disease‐modifying therapies like hydroxyurea for both patients and clinicians is essential to improving outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHumansAdultFemaleMaleMiddle AgedRetrospective StudiesYoung AdultHydroxyureaGeorgiaComorbidityAgedGenotype

Stichwörter der Autor:innen

end organ damagehydroxyurealife expectancymortalitysickle cell disease

Substanzen

Hydroxyurea

Autor:innen und Institutionen

  • Department of Internal Medicine, Morehouse School of Medicine, Atlanta, Georgia, USA.
  • Section of Hematology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.
  • Georgia Comprehensive Sickle Cell Center at Grady Health System, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Jennifer A Afranie-Sakyi, Ross Fasano, Morgan L McLemore, Fuad El Rassi

Zitieren

APA

Afranie-Sakyi, J. A., Randall, E., Fasano, R., McLemore, M. L., & El Rassi, F. (2025). The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center. European Journal of Haematology. https://doi.org/10.1111/ejh.14360

Vancouver

Afranie-Sakyi JA, Randall E, Fasano R, McLemore ML, El Rassi F. The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center. European Journal of Haematology. 2025. doi:10.1111/ejh.14360

BibTeX
@article{AfranieSakyi2025,
  author = {Afranie-Sakyi, Jennifer A and Randall, Eldrida and Fasano, Ross and McLemore, Morgan L and El Rassi, Fuad},
  title = {The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14360}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche